CD22-directed Immunoconjugate class drugs
1 result
Besponsa (inotuzumab ozogamicin)
(inotuzumab ozogamicin)Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Usage: BESPONSA is indicated for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients aged 1 year and older.